CLLS saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 80 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
CLLS moved below its 50-day moving average on September 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 174 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.551) is normal, around the industry mean (2.835). P/E Ratio (-1.625) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDGL declined for three days, in 259 of 327 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDGL as a result. In 69 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for MDGL turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 29 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
MDGL moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDGL crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for MDGL entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 222 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.840) is normal, around the industry mean (2.835). P/E Ratio (-32.147) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CLLS | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 21 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 94 | 63 | |
P/E GROWTH RATING 1..100 | 17 | 26 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (16) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLLS (60) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CLLS’s over the last 12 months.
MDGL's Profit vs Risk Rating (21) in the Pharmaceuticals Other industry is significantly better than the same rating for CLLS (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CLLS’s over the last 12 months.
MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CLLS (98) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CLLS’s over the last 12 months.
MDGL's Price Growth Rating (63) in the Pharmaceuticals Other industry is in the same range as CLLS (94) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CLLS’s over the last 12 months.
CLLS's P/E Growth Rating (17) in the Biotechnology industry is in the same range as MDGL (26) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.
| CLLS | MDGL | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 84% | 3 days ago 73% |
| Stochastic ODDS (%) | 3 days ago 83% | 3 days ago 77% |
| Momentum ODDS (%) | 3 days ago 90% | 4 days ago 78% |
| MACD ODDS (%) | 3 days ago 83% | 4 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 87% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 77% |
| Advances ODDS (%) | 21 days ago 79% | 21 days ago 76% |
| Declines ODDS (%) | 3 days ago 89% | 3 days ago 79% |
| BollingerBands ODDS (%) | 3 days ago 89% | 3 days ago 74% |
| Aroon ODDS (%) | 3 days ago 84% | 3 days ago 70% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 1 FA rating(s) are green while MDGL’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).
CLLS (@Biotechnology) experienced а -17.46% price change this week, while MDGL (@Biotechnology) price change was -4.67% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
CLLS is expected to report earnings on Nov 09, 2026.
MDGL is expected to report earnings on Oct 29, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.
| Ticker / NAME | Correlation To CLLS | 1D Price Change % | ||
|---|---|---|---|---|
| CLLS | 100% | -5.88% | ||
| SLN - CLLS | 43% Loosely correlated | -7.17% | ||
| MDGL - CLLS | 40% Loosely correlated | -2.19% | ||
| PMVP - CLLS | 38% Loosely correlated | -6.20% | ||
| AXON - CLLS | 36% Loosely correlated | -6.45% | ||
| TGTX - CLLS | 36% Loosely correlated | -3.62% | ||
More | ||||
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.
| Ticker / NAME | Correlation To MDGL | 1D Price Change % | ||
|---|---|---|---|---|
| MDGL | 100% | -2.19% | ||
| ALXO - MDGL | 56% Loosely correlated | +6.00% | ||
| IPHA - MDGL | 44% Loosely correlated | -3.38% | ||
| LCTX - MDGL | 43% Loosely correlated | -1.21% | ||
| CVM - MDGL | 43% Loosely correlated | +2.87% | ||
| VOR - MDGL | 42% Loosely correlated | -6.77% | ||
More | ||||